Pfizer And Lilly Announce Positive Results From Phase 3 Trial Of Tanezumab
INDIANAPOLIS (dpa-AFX) – Pfizer Inc.(PFE) and Eli Lilly and Co. (LLY) said that a 16-week Phase 3 study in patients with osteoarthritis or OA pain evaluating subcutaneous administration of tanezum…
FinanzNachrichten.de: Meistgelesene Nachrichten
